• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?
RESEARCH UPDATE

Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?

October 1, 2022
Sibel Algon, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Dr. Algon, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Patel RS et al, J Child Adolesc Psychopharmacol 2021;31(8):521–530 

STUDY TYPE: Systemic review and meta-analysis

Pediatric bipolar depression (PBD) is difficult to treat (see Dr. Charuvastra’s article, "Bipolar Spectrum Disorders in Children and Adolescents," on page 1) and often broadly defined. Currently there are only two FDA-approved medications: lurasidone and olanzapine/fluoxetine combination (OFC). In this meta-analysis, researchers sought well-designed studies of second-generation antipsychotics (SGAs) to see if there are alternatives to the currently approved treatments. 

The authors reviewed randomized controlled trials comparing SGAs to placebo in youth (<20 years old) with PBD and used Children’s Depression Rating Scale-Revised scores to calculate treatment response and number needed to treat (NNT). Of 569 studies, only four met complete inclusion criteria—one of OFC, one of lurasidone, and two of quetiapine—and all four were industry funded. 

The meta-analysis included 826 youths with PBD who received short-term treatment (six to eight weeks) with an SGA or placebo. Only those administered lurasidone or OFC were significantly more likely than their placebo counterparts to be treatment responders. The NNT was 4.3 for lurasidone and 5.3 for OFC. A subgroup analysis found effect sizes for lurasidone treatment that were five-fold higher in older teens versus younger children (DelBello MP et al, J Am Acad Child Adolesc Psychiatry 2017;56(12):1015–1025). A subsequent meta-analysis of the same four trials reported that lurasidone was associated with smaller increases in weight, cholesterol, triglycerides, and prolactin compared to OFC (DelBello MP et al, J Am Acad Child Adolesc Psychiatry 2022;61(2):243–254). Quetiapine was not more effective than placebo for PBD. 

Carlat Take
While we accept that lurasidone has fewer metabolic side effects, we are wary of the other results. PBD remains a controversial diagnosis, widening the boundaries from classical bipolar disorder and likely including cases of oppositional-defiant disorder, disruptive mood dysregulation disorder, complex posttraumatic stress disorder, and borderline personality disorder. The four trials and this review come from authors who advocate for this PBD construct, and this heterogeneous mixture probably includes cases that are less responsive to SGAs. The other concern is that we have not seen the raw data, and industry-funded studies may manipulate research design. We need independent studies on treatment of classical bipolar I depression that are not industry funded to give us firmer guidance in this area. (Editor’s note: See “Reading Research: Details Matter” in The Carlat Child Psychiatry Report, July/Aug/Sept 2021.)

Child Psychiatry
KEYWORDS bipolar bipolar depression child psychiatry mood disorders research update
Sibel Algon, MD.

More from this author
www.thecarlatreport.com
Issue Date: October 1, 2022
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
Bipolar Spectrum Disorders in Children and Adolescents
Assessing and Treating Catatonia in Children and Adolescents
Assessing Sensory Processing Challenges
Consider Catatonia in Your Differential
SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?
Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?
Ask the Editor: Is Silexan Safe for Children and Adolescents?
CME Post-Test, Catatonia in Children and Adolescents, CCPR, Oct/Nov/Dec 2022
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.